Key result
STEMI patients with simultaneous elevation of IL-6 and IL-10 (IL-6+IL-10+) had an increased risk of systolic dysfunction at discharge and death at 6 months compared with IL-6-IL-10+ patients.
Why the study?
Does the combination of elevated IL-6 and IL-10 levels predict worse clinical outcomes in patients with STEMI?
Observational (n=308)
Does the combination of elevated IL-6 and IL-10 levels predict worse clinical outcomes in patients with STEMI?
Answers are grounded in this paper and cite their sources.
May identify higher-risk STEMI patients; hypothesis-generating for cytokine profiling and requires prospective validation.
RATIONALE: At the onset of ST-elevation acute myocardial infarction (STEMI), patients can present with very high circulating interleukin-6 (IL-6(+)) levels or very low-IL-6(-) levels. OBJECTIVE: We compared these 2 groups of patients to understand whether it is possible to define specific STEMI phenotypes associated with outcome based on the cytokine response. METHODS AND RESULTS: We compared 109 patients with STEMI in the top IL-6 level (median, 15.6 pg/mL; IL-6(+) STEMI) with 96 in the bottom IL-6 level (median, 1.7 pg/mL; IL-6(-) STEMI) and 103 matched controls extracted from the multiethnic First Acute Myocardial Infarction study. We found minimal clinical differences between IL-6(+) STEMI and IL-6(-) STEMI. We assessed the inflammatory profiles of the 2 STEMI groups and the controls by measuring 18 cytokines in blood samples. We exploited clustering analysis algorithms to infer the functional modules of interacting cytokines. IL-6(+) STEMI patients were characterized by the activation of 2 modules of interacting signals comprising IL-10, IL-8, macrophage inflammatory protein-1α, and C-reactive protein, and monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, and monokine induced by interferon-γ. IL-10 was increased both in IL-6(+) STEMI and IL-6(-) STEMI patients compared with controls. IL-6(+)IL-10(+) STEMI patients had an increased risk of systolic dysfunction at discharge and an increased risk of death at 6 months in comparison with IL-6(-)IL-10(+) STEMI patients. We combined IL-10 and monokine induced by interferon-γ (derived from the 2 identified cytokine modules) with IL-6 in a formula yielding a risk index that outperformed any single cytokine in the prediction of systolic dysfunction and death. CONCLUSIONS: We have identified a characteristic circulating inflammatory cytokine pattern in STEMI patients, which is not related to the extent of myocardial damage. The simultaneous elevation of IL-6 and IL-10 levels distinguishes STEMI patients with worse clinical outcomes from other STEMI patients. These observations could have potential implications for risk-oriented patient stratification and immune-modulating therapies.
No takes yet. Share an insight, caveat, or question.
Ammirati et al. (2012) conducted an observational in ST-elevation acute myocardial infarction (STEMI) (n=308). Simultaneous elevation of IL-6 and IL-10 (IL-6+IL-10+ pattern) vs. IL-6-IL-10+ pattern and matched controls was evaluated on Systolic dysfunction at discharge and death at 6 months. STEMI patients with simultaneous elevation of IL-6 and IL-10 (IL-6+IL-10+) had an increased risk of systolic dysfunction at discharge and death at 6 months compared with IL-6-IL-10+ patients.
Synapse has enriched 10 related papers. Consider them for comparative context: